ePrints

Drug Insight: Antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation

Lookup NU author(s): Professor Azfar Zaman

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Antiplatelet therapy with aspirin and clopidogrel is standard care following revascularization by percutaneous coronary intervention with stent insertion. This so-called dual therapy is recommended for up to 4 weeks after intervention for bare-metal stents and for 6-12 months after intervention for drug-eluting stents. Although it is estimated that 5% of patients undergoing percutaneous coronary intervention require long-term anticoagulation because of an underlying chronic medical condition, continuing treatment with triple therapy (warfarin, aspirin and clopidogrel) increases the risk of bleeding. In most patients triple antithrombotic therapy seems justified for a short period of time. In some patients, however, a more considered judgment based on absolute need for triple therapy, risk of bleeding and risk of stent thrombosis is required, but the optimum antithrombotic treatment for these patients who require long-term anticoagulation has not been defined. This Review summarizes the existing literature concerning antithrombotic therapy and makes recommendations for initiation and duration of triple therapy in the small proportion of patients already receiving anticoagulant therapy who require percutaneous coronary intervention.

Publication metadata

Author(s): Helft G, Gilard M, Le Feuvre C, Zaman AG

Publication type: Review

Publication status: Published

Journal: Nature Clinical Practice Cardiovascular Medicine

Year: 2006

Volume: 3

Issue: 12

Pages: 673-680

ISSN (print): 1743-4297

ISSN (electronic): 1759-5010

URL: http://dx.doi.org/10.1038/ncpcardio0712

DOI: 10.1038/ncpcardio0712

PubMed id: 17122800

Share